SLS News and Press, SELLAS Life Sciences Group Inc. From 01/04/24

2024-01-04 09:07:20 ET More on SELLAS Life Sciences SELLAS Life Sciences announces launch of proposed public offering SELLAS provides corporate updates, shares up premarket Seeking Alpha’s Quant Rating on SELLAS Life Sciences For further details see: ...

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...

2024-01-04 01:32:00 ET More on SELLAS Life Sciences SELLAS provides corporate updates, shares up premarket SELLAS Life Sciences announces $4M registered direct offering priced at-the-market under Nasdaq rules Seeking Alpha’s Quant Rating on SELLAS Life Science...

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced that i...

2024-01-03 07:45:36 ET More on SELLAS Life Sciences SELLAS Life Sciences announces $4M registered direct offering priced at-the-market under Nasdaq rules Sellas Life Sciences stock jumps on FDA fast track designation for PTCL treatment Seeking Alpha’s Quant Ra...

- Company to Host Corporate Update Webinar Today, January 3, 2024, at 8:30 am ET- -Interim Analysis of Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia Expected in First Quarter 2024 - - Phase 2a Study of SLS009 in Relapsed/Refractory AML Patients On...

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is App...

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient with Complete Metabolic Response Continuing Treatment for over 62 weeks and anoth...

- Enrollment Completed in 45 mg Safety Cohort; Safety Monitoring Committee Advocated Proceeding to Recommended Phase 2 Dose Level of 60 mg - - Patients in 60 mg Dose Cohort Will be Dosed with 60 mg Once per Week or 30 mg Twice per Week - - Early Data in 45 mg and 60 mg Co...

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...